Beta-Blockers After PCI for Stable Coronary Artery Disease and Preserved Left Ventricular Ejection Fraction.

Background: Limited data exist on the long-term impact of beta-blocker therapy after percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) and preserved left ventricular ejection fraction (LVEF).

Objectives: The aim of the study was to evaluate the effects of early beta-blocker initiation vs no initiation following PCI in patients with stable CAD and preserved LVEF.

Methods: This retrospective cohort study employed target trial emulation and incident user design, utilizing the TriNetx database (2009-2024).

Skeletal Maturity Might Not Be a Factor in Optimizing Outcomes in Total Hip Arthroplasty.

Introduction Total hip arthroplasty (THA) is rarely indicated in the skeletally immature population. In these instances, there is concern for implant survival compared to the traditional older population. There has been a steady rise in the use of THA in the pediatric population due to improvements in surgical techniques.

Trends in screening and treatment of osteoporosis after periprosthetic fractures from 2010 to 2020.

Unlabelled: Osteoporosis is often underrecognized and undertreated following periprosthetic fractures (PPF). Our study found that between 2010 and 2020, there has been no significant change in the rates of osteoporosis screening or treatment within 1 year following PPF. Orthopedic surgeons can play an integral role in helping to curtail the osteoporosis epidemic.

Hormone Replacement Therapy in Postmenopausal Women Undergoing Total Hip Arthroplasty is Associated With Reduced 10-Year Periprosthetic Femoral Fracture Rate.

Background: In postmenopausal women who are estrogen deficient, hormone replacement therapy (HRT) has been shown to improve fragility fracture risk. However, few studies have examined the relationship between HRT and periprosthetic fracture (PPF) risk after total hip arthroplasty (THA). The purpose of this study was to determine the impact of HRT use on 10-year PPF risk following THA.